For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval >= 24 weeks must have elapsed from completion of radiation therapy (XRT) to registration
Participants who have received prior treatment with interstitial brachytherapy, stereotactic radiosurgery, or implanted chemotherapy sources, such as wafers of polifeprosan 20 with carmustine
Participant is deemed to be an appropriate candidate for MRI-guided brachytherapy by the radiation oncologist and the patient elects to be treated with MRI-guided brachytherapy
Must have completed and recovered from all prior definitive therapy (surgery, brachytherapy, cryotherapy or radiotherapy) for the primary tumor, or other definitive-intent local therapy
Received prior local therapy (stereotactic radiosurgery, brachytherapy, or carmustine wafers) to the proposed area of MLA treatment
For brachytherapy, an IPSS ? 21, or ? 17 if patient is on medications to improve urination.
For brachytherapy, prostate volume must be less than 55cc prior to AS.
Pathologically confirmed malignancy for which high-dose rate brachytherapy is appropriate as a component of their therapeutic regimen
Cervical cancer\r\n* Patients who are unable to undergo surgery and must have treatment for an inoperable primary cervical cancer\r\n* Patients with locally advanced cervical cancer in whom brachytherapy will be integrated as a boost to external beam radiation either a palliative or curative setting (definitive or postoperative setting)
Prostate cancer\r\n* Patients with localized prostate cancer (T1b-T3b) in whom brachytherapy will be integrated as a boost to external beam radiation or used as monotherapy for definitive management
Any patient or tumor/anatomical factors that may prevent brachytherapy apparatus from being properly and safely inserted and positioned and from radiation therapy being administered per American Brachytherapy Society (ABS) guidelines
Any prior or current treatment for prostate cancer, including surgery, radiation therapy (external or brachytherapy) or chemotherapy;
Patients must have histologically confirmed locally recurrent adenocarcinoma of the prostate after prior radiation (external beam radiation therapy [EBRT] or brachytherapy)
Prior local non-surgical therapy to treat prostate cancer (e.g. radiation therapy, brachytherapy)
Patients must not have had prior treatment of glioblastoma with stereotactic radiosurgery, brachytherapy, or carmustine-impregnated wafers (Gliadel).
Has received prior interstitial brachytherapy, implanted chemotherapy, stereotactic radiosurgery or therapeutics delivered by local injection or convection enhanced delivery
Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)
Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)
Prior local therapy to treat prostate cancer (e.g. radical prostatectomy, radiation therapy, brachytherapy)
Patients with previous history of radiosurgery, brachytherapy, Gliadel implantation, or radiolabeled monoclonal antibodies
Has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery; prior treatment with Gliadel wafers will be excluded
Prior radiation of any kind to the prostate gland or pelvis\r\n* Prior brachytherapy is not allowed
Prior cryosurgery, high intensity focused ultrasound (HIFU) or brachytherapy of the prostate
Patients assessed at presentation as requiring interstitial brachytherapy treatment
Prior cryosurgery, high-intensity focused ultrasound ablation (HIFU) or brachytherapy of the prostate
Patients may not be receiving any other investigational agents or have received any definitive prostate cancer (PCa)-specific treatment (en-bloc resection of bladder tumors [EBRT], Brachytherapy etc) prior
Has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery. Prior treatment with Gliadel wafers will be excluded. Concomitant use of the Optune device will also be excluded.
Any prior treatment for prostate cancer \r\n* Radical prostatectomy \r\n* Radiation therapy (external beam or brachytherapy) \r\n* Cryotherapy \r\n* High intensity focused ultrasound treatment \r\n* Photodynamic therapy \r\n* Androgen deprivation therapy
Prior radiation therapy, brachytherapy, or cryotherapy
Patients assessed at presentation as requiring interstitial brachytherapy treatment
No prior interstitial brachytherapy or stereotactic radiosurgery unless area of assessment and planned resection is outside the region previously treated.
Prior placement of Gliadel wafer or local brachytherapy
The patient has decided to undergo brachytherapy (or brachytherapy plus external beam radiation) as a treatment modality for his prostate cancer
Histologically confirmed recurrent adenocarcinoma of the prostate =< 1 year prior to registration and >= 18 months following localized treatment of: \r\n* EBRT or\r\n* Permanent prostate brachytherapy or\r\n* High dose rate brachytherapy or\r\n* Any combination of the above radiotherapy treatments or\r\n* Prostatectomy; patients who have a localized recurrence following prostatectomy with a discernible mass identifiable on trans-rectal ultrasound that can be readily accessed as judged by the treating urologist or radiation oncologist
Has received prior interstitial brachytherapy, implanted chemotherapy, or therapeutics delivered by local injection or convection enhanced delivery
Has received prior interstitial brachytherapy, implanted chemotherapy, stereotactic radiosurgery or therapeutics delivered by local injection or convection enhanced delivery
Patients should have any of the below to be eligible\r\n* Are not candidates for intracavitary brachytherapy due to poor geometry or poor response to external beam radiation therapy (RT)\r\n* Patients with co-morbid medical conditions, bleeding disorders, poor anesthetic risk precluding brachytherapy\r\n* Patients who refuse brachytherapy or prefer external beam hypofractionated approach\r\n* Patients requiring interstitial brachytherapy\r\n* Note: patients may be discovered during standard therapy and enrolled prior to boost
Patients must have received prior radiotherapy for meningioma; patients may have received standard external beam radiation, interstitial brachytherapy, or radiosurgery in any combination; an interval of >= 4 weeks (28 days) must have elapsed from the completion of radiotherapy to study entry and there must be subsequent evidence of tumor progression; patients with prior interstitial brachytherapy or stereotactic radiosurgery must have confirmation of true progression disease rather than radiation necrosis based on positron emission tomography (PET), MR-perfusion, MR-spectroscopy, or surgical documentation of disease; if there is any question, investigators should discuss with the MSKCC principal investigator (PI)
Patients previously treated with stereotactic radiosurgery, stereotactic radiotherapy, brachytherapy, Gliadel wafers or other intratumoral chemotherapy are eligible
Patients who have had prior stereotactic radiotherapy, convection enhanced delivery or brachytherapy as gliosis/scarring from these modalities may limit delivery; however, if a patient has a resection or biopsy at the site of prior stereotactic radiotherapy, convection enhanced delivery, or brachytherapy and the biopsy specimen shows recurrent GBM and EGFR amplification by FISH, the patient will be eligible; patients with recurrence outside the radiosurgery field will be considered for eligibility if the recurrence is clearly documented to be outside the field and more than 3 months have lapsed since the last dose of radiosurgery
Patient has either metastatic disease (M1; stage IVB), is medically unable to receive brachytherapy, or refuses brachytherapy
Patients who have received prior hormonal or surgical therapy for prostate cancer; including prior brachytherapy or radiation therapy
Patient has had surgery or initiated radiation therapy (brachytherapy or external beam radiation) or initiated pre-radiation androgen deprivation therapy within the last 12 months
Treatment with primary radiation (brachytherapy or external beam therapy), radiation + androgen deprivation therapy (ADT) or salvage prostatectomy
Completed either radical prostatectomy (Group 1 or Group 3) or radiation therapy (external beam radiation therapy or brachytherapy; Group 2 or Group 3) within the past 12 months
Completed either radical prostatectomy or radiation therapy (external beam radiation therapy or brachytherapy) within the past 12 months
Within one year completion of either radical prostatectomy or radiation therapy (external beam radiation therapy or brachytherapy)
Undergone or is planning to undergo brachytherapy with transpapillary or percutaneous implantation of intracavitary radiation sources
Use of pulmonary airway stents and/or ongoing or initiation of local external beam or brachytherapy radiation
Received prior radical prostatectomy (with or without post-operative radiation) or definitive local radiation for prostate cancer (either external beam radiation, brachytherapy, or combination)
History of orchiectomy, PCa-specific chemotherapy, brachytherapy, cryotherapy, Photodynamic therapy or radical prostatectomy for treatment of prostate cancer; any prior radiation therapy to the pelvis for prostate cancer or any other malignancy.
Patients with biopsy proven (completed and/or reviewed at Memorial Sloan-Kettering [MSK]) adenocarcinoma of the prostate, who will undergo external beam radiotherapy using conventional fractionation image-guided radiotherapy (IGRT) including moderate hypofractionated radiation, low rate brachytherapy alone, low dose brachytherapy combined with supplemental image guided radiation (including IGRT, external beam radiation therapy [EBRT], and stereotactic body radiation therapy [SBRT]), SBRT, or proton radiotherapy
In the case of cryotherapy, external beam radiation, or high-intensity focused ultrasound therapy (HIFU) the procedure will have occurred at least one year in the past; in the case of brachytherapy, treatment will have occurred at least 2 years in the past to eliminate patients with so-called “prostate-specific antigen (PSA) bump”
Less than 1 year since cryotherapy, external beam radiation therapy, or HIFU, or 2 years since brachytherapy; does not meet above criteria of suspicious PSA elevation
Prior treatment of prostate cancer including brachytherapy, radiation therapy, cryosurgery, high-intensity focused ultrasound (HIFU), or vaccine therapy
Radiotherapy (external beam irradiation alone or in combination with hormonal therapy and/or brachytherapy) was delivered as definitive therapy for prostate cancer and documentation is available
Patient is unable to receive high dose rate prostate brachytherapy
Prior prostate cancer-directed therapy including:\r\n* Androgen deprivation therapy\r\n* Radiation therapy to the prostate (external beam or brachytherapy)\r\n* Cryotherapy\r\n* High-intensity focused ultrasound (HIFU)\r\n* Chemotherapy for prostate cancer
In the case of cryotherapy, external beam radiation, or high intensity focused ultrasound (HiFU) the procedure will have occurred at least one year in the past; in the case of brachytherapy, treatment will have occurred at least 2 years in the past to eliminate patients with so-called “PSA bump”
Less than 1 year since cryotherapy, external beam radiation therapy, or HiFU, or 2 years since brachytherapy
Salvage radical prostatectomy, i.e., patients having surgery due to failure of previous therapy (radiation, brachytherapy, cryotherapy, etc.)
Previous brachytherapy treatment will have occurred at least 2 years in the past
Salvage radical prostatectomy, i.e., patients having surgery due to failure of previous therapy (radiation, brachytherapy, cryotherapy, etc.)
Brachytherapy with EBRT in subjects whose prostate volume is >60cc
Patients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapy
History of radiation therapy, either via external beam or brachytherapy within 28 days prior to registration
Patients who have received prior prostate or pelvic radiotherapy, including external beam or brachytherapy
No prior radiation therapy (external beam or brachytherapy) to the pelvis or prostate
Patient has received any pelvic radiotherapy (including external beam and/or brachytherapy).
Has received any pelvic radiotherapy (including external beam and/or brachytherapy.)
Radiation therapy via external beam or brachytherapy within 28 days of registration
Current or prior pelvic external beam radiotherapy within 5 years of entry
Patient has received any pelvic radiotherapy (including external beam and/or brachytherapy.)
Prior pelvic external beam radiotherapy (EBRT)
Patients cannot have previously received pelvic external beam radiation or brachytherapy; patients may be enrolled while undergoing vaginal brachytherapy radiation treatment
Patients who have received prior pelvic external beam radiation or brachytherapy will be excluded
Prior pelvic external beam radiation therapy (RT).
SUB-STUDY I: Prior pelvic external beam radiation therapy or brachytherapy
SUB-STUDY II: Prior pelvic external beam radiation therapy or brachytherapy
Prior pelvic external beam radiation therapy or brachytherapy
Prior external beam, proton, or brachytherapy to the prostate
Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Patients judged capable of tolerating a radical course of chemoradiation therapy
Pathologically (histologically) proven diagnosis of prostate adenocarcinoma; prostatectomy must have been performed within 10 years prior to Step 1 registration and any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted
Patients must be deemed unfit for radical cystectomy by the treating physician, or the patient must refuse radical cystectomy, which is considered standard of care for these patients; the reason for patients not to undergo cystectomy will be clearly documented
Subject must have histologically-confirmed diagnosis of prostate adenocarcinoma and have received primary surgical management by radical prostatectomy
Prior radical prostatectomy
Subjects with NMIBC must be suitable for and willing to undergo a radical cystectomy at the completion of study therapy
Patients who are not appropriate surgical candidates for radical prostatectomy based on the evaluation of co-existent medical diseases and competing potential causes of death (such as but not limited to, unstable angina, myocardial infarction within the previous 6 months, or use of ongoing maintenance therapy for life-threatening ventricular arrhythmia, uncontrolled hypertension)
Gleason sum of 7 (with pT3 disease), 8, 9, or 10 based on the radical prostatectomy specimen
Men who will receive radical prostatectomy to the primary site
Gleason 7 – 10, cT2a – cT3b adenocarcinoma of the prostate with plans for radical prostatectomy
Localized or locally advanced disease deemed by the surgeon to be resectable. Patients must be appropriate candidates for radical prostatectomy plus pelvic lymph node dissection.
AT SCREENING: Serum chemistries, renal and liver panels within institutional normal limits or meets the requirements for radical prostatectomy.
Disease that can be encompassed within a radical radiotherapy treatment volume
Histological confirmation of adenocarcinoma of the prostate, >= Gleason 6, clinical stage T1a-T2c and planned for radical prostatectomy
Histopathologically proven adenocarcinoma, Gleason grade ? 7 of the prostate planned radical prostatectomy; appropriate for treatment with paclitaxel therapy
Patients must have histologically or cytologically confirmed prostate cancer (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaP
Patients must be a surgical candidate for radical prostatectomy based on standard workup of PSA, biopsy results, and if necessary supplemental imaging
Patients must have chosen radical prostatectomy as their definitive treatment of choice for management of their prostate cancer
Radical prostatectomy has been scheduled at Johns Hopkins Hospital
Patients must have histologically or cytologically confirmed cancer of prostate (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaP
Adenocarcinoma of the prostate with histological or cytological confirmation without neuroendocrine differentiation or small cell histology and with G 4+3 or higher, and PSA >= 10, and >= T2b, for whom radical prostatectomy has been recommended and who choose to undergo radical prostatectomy
Scheduled to undergo robotic radical prostatectomy
Ineligible for radical cystectomy or refusal of radical cystectomy
Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Bilateral orchidectomy or radical prostatectomy
Adenocarcinoma of the prostate treated primarily with radical prostatectomy\r\n* Any type of radical prostatectomy is permitted including retropubic, perineal, laparoscopic or robotically assisted; there is no time limit for the date of radical prostatectomy
History of radical prostatectomy, external beam radiotherapy (EBRT), or BT for prostate cancer
Previous radical surgery (prostatectomy), cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer
Status post radical prostatectomy for histologically confirmed adenocarcinoma of the prostate
Patients ineligible if the time interval between radical prostatectomy and the first day of randomization exceeds 3 months (+/- 2 weeks)
Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Patients must be regarded as acceptable surgical risk for radical prostatectomy and confirm their intention to undergo radical prostatectomy at the end of the pre-surgical therapy
Prior radical surgery (prostatectomy), high-intensity focused ultrasound (HIFU) or cryosurgery for prostate cancer
Patients who have had any form of prior prostate treatment (radical prostatectomy, radiotherapy, cryotherapy, high intensity focused ultrasound) will not be eligible
Radical surgery for carcinoma of the prostate
Status post definitive local therapy (radical prostatectomy) for pathological proven prostate cancer
Must be candidates for radical prostatectomy and considered surgically resectable by urologic evaluation.
Patient is ineligible, declines, or is considered ineligible to undergo radical cystectomy
History of histologically confirmed, clinical localized adenocarcinoma of the prostate treated with radical prostatectomy with definitive intent
Patients have elected to undergo radical prostatectomy (RP) as treatment of choice and have to be a surgical candidate for RP; this determination will be made by the patient in conjunction with their treating urologist and is current standard of practice
Prior radical prostatectomy
Patients must have histologically or cytologically confirmed carcinoma of the prostate (CaP); CaP can be recurrent disease after definitive therapy (radical prostatectomy or radiation therapy) for localized CaP, or metastatic CaP
Indication for radical cystectomy for urothelial cancer
Must have had radical surgical resection (e.g. radical cystectomy), performed within the last 120 days
No prior radical prostate surgery
Subjects desire focal therapy and decline conventional treatment (active surveillance, radical prostatectomy, radiation therapy, cryosurgery and hormone therapy)
Prostate cancer initially treated by radical prostatectomy or radiotherapy (including brachytherapy) or both, with curative intent;
Radical surgery for carcinoma of the prostate
Patients must be suitable for and willing to undergo a radical prostatectomy at the completion of study therapy
Adenocarcinoma of the prostate treated primarily with radical prostatectomy\r\n* Any type of radical prostatectomy will be permitted, including retropubic, perineal, laparoscopic, or robotically assisted; there is no time limit for the date of radical prostatectomy
Have chosen a radical prostatectomy for treatment of their disease after the medical team has presented all possible treatment options
Prior radical prostatectomy or cryosurgery for prostate cancer or bilateral orchiectomy
Indicated for radical prostatectomy\r\n* Note: candidates for radical prostatectomy are still eligible even if they have a history of deep venous thrombosis, pulmonary embolism, and/or cerebrovascular accident or currently requiring systemic anticoagulation
Prior radical prostatectomy or cryosurgery for prostate cancer
Prior radical surgery (prostatectomy), high-intensity focused ultrasound (HIFU) or cryosurgery for prostate cancer
Prior radical prostatectomy or bilateral orchiectomy for any reason
Patients must be eligible for radical cystectomy and refuse this standard of care treatment or not be a surgical candidate for radical cystectomy based on other comorbidities
Patients must be a surgical candidate for radical prostatectomy based on standard workup of PSA, biopsy results, and if necessary supplemental imaging
Patients must have chosen radical prostatectomy as their definitive treatment of choice for management of their prostate cancer
COHORT A: The subject must be deemed medically fit for radical prostatectomy by the attending urologic surgeon at the selected study site
Patients must have received primary treatment with radical prostatectomy
Baseline post-radical prostatectomy (RP) PSA =< 0.4
Scheduled for radical prostatectomy surgery
Resected lymph nodes must be provided for all subjects for biomarker analysis immediately (same day) after surgery (radical prostatectomy)
Rising PSA after prior definitive local therapy (radical prostatectomy, external beam radiation, or brachytherapy) or combination of radical prostatectomy and radiotherapy with curative intent
Minimum PSA 1.0 ng/mL if prior radical prostatectomy +/- adjuvant or salvage radiation; nadir + 2.0 ng/mL if prior RT without prior radical prostatectomy
Patients must have undergone local treatment via radical prostatectomy\r\n* Patients who have received primary radiation therapy followed by a salvage radical prostatectomy are eligible\r\n* Patients who have had post-operative radiation therapy for presumed locally recurrent disease are eligible
Patient must have a history of prostatectomy (Open Radical or Robotic Assisted) with histopathologic documentation of adenocarcinoma of the prostate
Planning to have or have had a radical prostatectomy (RP) at MSKCC
Prior radical prostatectomy or cryosurgery for prostate cancer or bilateral orchiectomy
Patients must be appropriate candidates for radical prostatectomy with an estimated life expectancy > 10 years as determined by a urologist; evidence of underlying cardiac disease should be evaluated prior to enrollment to ensure that patients are not at high risk of cardiac complications
Previous radical surgery (prostatectomy) or cryosurgery for prostate cancer
Subjects must have histologically confirmed local adenocarcinoma of the prostate and have elected to proceed with radical prostatectomy as the primary curative therapy
Must be a candidate for radical prostatectomy
Candidate for radical prostatectomy
Localized or locally advanced disease deemed by the surgeon to be resectable; patients must be appropriate candidates for radical prostatectomy plus pelvic lymph node dissection
Serum chemistries within institutional normal limits or requirements for radical prostatectomy
Renal panels within institutional normal limits or requirements for radical prostatectomy
Liver panels within institutional normal limits or requirements for radical prostatectomy
Planned elective radical prostatectomy with bilateral nerve sparing technique that can include high or low fascia
Judged by the study doctor to be a suitable candidate for a radical prostatectomy
Patients scheduled for radical prostatectomy for the treatment of prostate cancer with one of the consenting surgeons at MSKCC
Patients scheduled for minimally-invasive radical prostatectomy for the treatment of prostate cancer with one of the consenting surgeons at MSKCC
Subjects must have prostate cancer being treated via radical prostatectomy by a single surgeon (primary investigator) with planned intraoperative nerve sparing.
Is scheduled to undergo radical prostatectomy (i.e. robot-assisted or open-approach)
Is NOT scheduled to undergo radical prostatectomy (i.e. robot-assisted or open-approach)
Patients scheduling to undergo robot-assisted radical prostatectomy
Patients with prostate cancer who are electing to undergo robotic radical prostatectomy with pelvic lymph node dissection at The Arthur G. James Cancer Hospital and Solove Research Institute, The Ohio State University Medical Center by Dr. Ronney Abaza
Patients who undergo an open, elective radical cystectomy
Have treatment with radical prostatectomy or radiation treatment > 3 months prior to enrollment, if receiving these treatments
Men recently treated (within 3 months) with radical prostatectomy or radiation
Anticipated radical cystectomy with ileal conduit or orthotopic neobladder
Are currently being treated or have decided on their treatment process (radical prostatectomy or radiation therapy)
Patients undergoing minimally invasive radical-prostatectomy (including robotic and laparoscopic) at Washington University in Saint Louis (WUSTL)/Siteman Cancer Center (SCC)
Participants recruited from the community must be scheduled for radical prostatectomy or have undergone RP within the past 12 months for clinically diagnosed prostate cancer
Patient unsuitable for or refusing radical cystectomy
Completed radical prostatectomy for pathologically-verified adenocarcinoma of the prostate no more than 120 days prior to enrollment; the following procedures are acceptable: radical retropubic prostatectomy (RRP), laparoscopic radical prostatectomy (with or without robotic assistance; LAPD), radical perineal prostatectomy (RPP)
Patients who do not undergo radical cystectomy will be withdrawn from the study
The subject is scheduled to undergo radical prostatectomy
Subjects scheduled for robotic assisted radical prostatectomy for removal of localized prostate cancer;
Scheduled or planned radical prostatectomy with PLND. Cohort B Only: [Enrollment is complete; No longer recruiting subjects]
History of radical prostatectomy
Adenocarcinoma of the prostate, post radical-prostatectomy
Radical prostatectomy as definitive treatment for PCa
Men scheduled for transrectal prostate biopsy or radical prostatectomy at Columbia University Medical Center
Prostate cancer patients who have undergone radical prostatectomy
Radical prostatectomy within one year of enrollment
Planned radical prostatectomy at UCSF within 12 weeks following protocol MRI/MRSI
Patients must be eligible for and must be planning to undergo radical prostatectomy
INCLUSION CRITERIA (NEXT 60 PATIENTS WITH LOCALLY ADVANCED PROSTATE CANCER): Scheduled to undergo surgical resection with radical prostatectomy and lymphadenectomy
History of adenocarcinoma of the prostate treated with radical prostatectomy
History of prior radical prostatectomy for prostate cancer
Planned to undergo radical prostatectomy and extended pelvic lymph node dissection
Cohort A only (N = 5 evaluable patients):- Planned radical prostatectomy within 12 weeks following protocol scan
History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).
Received any neo-adjuvant prostate cancer treatment before radical prostatectomy
Men newly diagnosed with PCa who are scheduled for radical prostatectomy (RP) (stage T1 or T2)
Adenocarcinoma of the prostate with planned radical prostatectomy (RP) with curative intent as part of standard of care management plan
Patient is a candidate for radical prostatectomy
Patient scheduled for radical retropubic prostatectomy
Deemed to not be a candidate for radical cystectomy by attending urologic oncologist or refuse radical cystectomy
Patients post-prostatectomy with baseline Gleason >= 7 (per prostatectomy pathology)
Pathologically (histologically) proven diagnosis of adenocarcinoma of the prostate as confirmed at time of prostatectomy; prostatectomy must have been performed =< 365 days (1 year) prior to step 1 registration any type of radical prostatectomy is permitted, including retropubic, perineal, laparoscopic or robotically assisted; (please note: Prior ablative treatment for benign prostatic hypertrophy or focal high-intensity focused ultrasound therapy [HIFU] prior to prostatectomy is allowed)
Gleason sum of 7, 8, 9, or 10 at the time of prostatectomy
Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.
Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery.
Patient and urologist must agree that patient is suitable for prostatectomy
Indications for post-prostatectomy radiation exist:\r\n* Disease progression (detectable PSA on two measurements obtained at least one month apart) or\r\n* Indications for adjuvant radiation exist (if undetectable PSA): pathologic T3, T4, N+ disease or positive margins (within 1 year of prostatectomy)
If have untreated primary prostate cancer: must undergo debulking prostatectomy
Patient is suitable for prostatectomy.
Prior prostatectomy
Diagnosis of prostate cancer undergoing prostatectomy
Willing to use appropriate contraception from time of NanoPac® injection until prostatectomy
Prior prostatectomy
Prior local therapy with prostatectomy required, with available tissue from prostatectomy specimen to send for genomic and transcriptomic testing; specifically, either formalin-fixed paraffin-embedded (FFPE) blocks or 35-40 unstained slides from the primary prostatectomy specimen will need to be available for central pathologic review and processing
No prior prostatectomy or prostatic radiation
Prior prostatectomy
Willingness to use barrier contraception from the time of first dose of MGA271 until the time of prostatectomy
Willing to undergo prostatectomy as primary treatment for localized prostate cancer
Prior total prostatectomy or cryotherapy of the prostate
Patients who received hormone therapy before prostatectomy
Previous prostatectomy, cryosurgery, or high intensity focused ultrasound (HIFU) for prostate cancer
Previous prostate cancer surgery to include: prostatectomy, hyperthermia and cryosurgery
No prior prostatectomy or cryotherapy of the prostate
Neoadjuvant hormonal therapy prior to radical prostatectomy is allowed, and post-prostatectomy hormonal therapy is allowed only if the onset of androgen ablation is =< 90 days prior to the date of registration
Presence of multiple small bowel loops trapped within the immediate tumor bed (post hysterectomy or prostatectomy)
A post-radical prostatectomy study entry PSA >= 45 days after prostatectomy and within 30 days prior to step 1, < 2.0 ng/mL
Androgen deprivation therapy started prior to prostatectomy for > 6 months (180 days) duration; \r\n* Note: The use of finasteride or dutasteride (± tamsulosin) for longer periods prior to prostatectomy is acceptable
History of salvage prostatectomy
Patients must have undergone local treatment via prostatectomy or radiation therapy
Prior prostatectomy
History of diagnosis of prostate cancer after undergoing prostatectomy
Scheduled to undergo a prostatectomy at Johns Hopkins
Subjects must be able to safely be on lithium carbonate treatment for a period of at least four weeks prior to the scheduled prostatectomy
Completion of appropriate prior treatment with local therapy (i.e., prostatectomy, radiation therapy or equivalent), per National Comprehensive Cancer Network (NCCN) guidelines
Patients having robotic prostatectomy.
Prostatectomy with or without radiation for the pilot study patients only
Planned SRT for recurrence after primary prostatectomy.
SUB-STUDY I: No prostatectomy scheduled more than 12 hours post imaging
Patients will have been originally diagnosed with prostate carcinoma and have undergone what was considered definitive non-prostatectomy therapy for localized disease
Patients with a malignancy within the past 3 years for which study drugs or a prostatectomy is a contraindication
No prior local therapy (prostatectomy, radiation, cryotherapy) or hormonal therapy for prostate cancer
Prostatectomy at M. D. Anderson within 3 months from the time of MRSI
Patients will have been originally diagnosed with localized (stage T1c, T2, or T3) prostate carcinoma and have undergone what was considered definitive non-prostatectomy therapy for localized disease
Greater than T3 disease in past and/or treated with prostatectomy
All men undergoing robotic prostatectomy or cystoprostatectomy at City of Hope will be eligible for the study
Patients who have had prior prostatectomy or prior androgen therapy
Prior history of prostatectomy
